Keyue Bs Chen

Keyue Bs Chen

Auto-generated profile, based on publicly available information

Keyue Bs Chen

University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in Ultrasound Quarterly
Verified
Journal Article
Closed access
HSHaolin Shen
Haolin Shen
GLGuorong Lyu
Guorong Lyu
TLTingting Bs Li
Tingting Bs Li
YWYuegui Bs Wang
Yuegui Bs Wang
KCKeyue Bs Chen
Keyue Bs Chen
SYShuping Yang
Shuping Yang
To establish and validate a nomogram for predicting lymph node metastasis (LNM) of papillary thyroid carcinoma (PTC) in the cervical central region. This retrospective study included 287 PTC patients with 309 nodules treated from December 2018 to May 2020 at our hospital. The cohort was divided randomly into a training set and a testing set according to a 7:3 ratio. The training set contained 216 nodules, and the testing set contained 93 nodules. The nomogram was developed using the training set, and the data of the testing set were used to validate the performance of nomogram. The predictive accuracy and discriminative ability of the nomogram were determined by concordance index (C-index) and calibration curve. The study showed multifocality, thyroid lesion size, and American College of Radiology Thyroid Imaging, Reporting and Data System (TI-RADS) score were significantly independently associated with LNM in the cervical central region. In the testing set, the calibration curve showed that the nomogram had good discrimination with a C-index of 0.775 (95% confidence interval, 0.680–0.869) and adequate calibration (P = 0.808). By decision curve analysis and clinical impact curve analysis, the nomogram was shown to have a satisfactory net benefit between thresholds of 0.40 and 0.75. The nomogram can be used for predicting LNM of PTC in the cervical central region and may provide valuable guidance for planning the surgical treatment of PTC patients.

15 November 2022 in Cancer Research
Verified
Journal Article
Open access
DLDaniel K.C. Lee
Daniel K.C. Lee
RLRyan Loke
Ryan Loke
LTLydia To
Lydia To
KCKeyue Chen
Keyue Chen
JCJonathan T.S. Chow
Jonathan T.S. Chow
LSLeonardo Salmena
Leonardo Salmena
Background: Pancreatic Cancer (PC) is one of the most aggressive cancer types, with less than 10% of patients surviving at 5-years. One hallmark of PC is the frequent mutation of the oncogene KRAS resulting in the constitutive activation of the phosphoinositide-3-kinase (PI3K) signaling pathway. The PI3K pathway is an intracellular signaling pathway that regulates cell growth, metabolism, and survival in response to extracellular signals. Given the importance of deregulated phosphoinositide (PI) signaling in PC, we hypothesize that genes coding for PI-metabolizing enzymes and effectors may have significant and unappreciated roles in PC. Methods: We generated a CRISPR knockout (KO) library that targets 1,534 PI-associated genes to discover novel essential genes in PC. Results: In a PANC-1 screen, we identified 106 essential genes across all timepoints, including 28 novel candidate genes and 78 previously identified essential genes. Among six validated candidate genes, we demonstrate that Integrin Subunit Alpha V (ITGAV) is a protein with clinical importance in PC. Treatment of PC cell lines with an ITGAV integrin antagonist as well as KO of ITGAV resulted in reduced cancer associated phenotypes in vitro, including reduced proliferation rate and compromised migration and invasion capacity. Ongoing studies will investigate perturbations in signaling pathways associated with ITGAV, and aim to elucidate roles for ITGAV in metastatic progression and therapy response. Conclusions: Overall, these findings indicate that ITGAV inhibition represents a putative strategy for the treatment of PC. Citation Format: Daniel K.C. Lee, Ryan Loke, Lydia To, Keyue Chen, Jonathan T.S. Chow, Leonardo Salmena. Phosphoinositide focused CRISPR screen reveals ITGAV as a critical gene in pancreatic cancer growth and invasion [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr B024.